We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Cryoablation for Phantom Limb Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02366832
Recruitment Status : Completed
First Posted : February 19, 2015
Last Update Posted : March 22, 2017
Boston Scientific Corporation
Information provided by (Responsible Party):
John Prologo, Emory University

Brief Summary:
The purpose of this study is to determine if treatment with percutaneous cryoablation yields significant differences in the evaluative criteria of Phantom Limb Syndrome (PLS).

Condition or disease Intervention/treatment Phase
Phantom Limb Syndrome Procedure: Cryoablation Device: 17g Galil Medical Ice Sphere cryoablation needle Not Applicable

Detailed Description:
This study aims to treat Phantom Limb Syndrome (PLS) with cryoablation of the remaining nerve stumps. The rationale is that because the pain in PLS follows the known distribution of nerves, and because the amputated nerves are known to undergo changes after the surgery that may lead to excessive "firing," that interruption of the nerve impulses will reduce patient pain.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Percutaneous Image Guided Cryoablation for the Treatment of Refractory Phantom Limb Pain
Actual Study Start Date : February 2015
Actual Primary Completion Date : December 16, 2016
Actual Study Completion Date : December 16, 2016

Arm Intervention/treatment
Experimental: Cryoablation
Amputee subjects experiencing phantom limb syndrome (PLS) will receive cryoablation
Procedure: Cryoablation
Subjects who respond to lidocaine nerve block will undergo CT guided cryoablation of the affected nerve stump with a 17g Galil Medical Ice Sphere cryoablation needle.
Other Names:
  • Cryotherapy
  • Cryosurgery

Device: 17g Galil Medical Ice Sphere cryoablation needle
Under CT guidance, the corresponding nerve will be targeted with a 17g probe. Two freeze-thaw cycles will be undertaken. The probe will be removed and a final scan obtained.

Primary Outcome Measures :
  1. Feasibility of cryoablation, defined by number of participants, in which cryoablation was performed successfully [ Time Frame: Post-Cryoablation ]
    Feasibility, defined by number of participants, in which cryoablation was performed successfully

  2. Safety of cryoablation procedure, measured by the number of subjects that had cryoablation procedure events (CPEs). [ Time Frame: 56 days ]
    Safety is measured by the number of subjects that had cryoablation procedure events (CPEs). CPEs are device- or procedure-related serious adverse events (SAE) or adverse events (AE) categorized as clinical signs or symptoms of infection (fever), hemorrhage (pain, imaging changes), nerve pain worsening, or toxicity of any kind (confusion, seizure).

Secondary Outcome Measures :
  1. Change in pain scores on visual analogue scale (VAS ) [ Time Frame: Baseline, day 56 ]
    Change in pain score will be calculated by subtracting the day 56 pain score from the baseline pain score.The pain scores are on a continuous visual analogue scale of 0 to 100 mm. 0 mm = no pain and 100 mm = worst possible pain. The VAS is scored simply by measuring the distance, in mm, from the patient's mark to one of the ends of the line.

  2. Change in quality of life, measured using Roland-Morris Disability Questionnaire (RDQ) [ Time Frame: Baseline, day 56 ]
    Quality of life will be measured using Roland-Morris Disability Questionnaire (RDQ); it is a validated measure of physical disability due to low back pain.The best score is 0 (no disability) and worst is 24 (maximum disability).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects are status post (s/p) amputation of an upper or lower limb. That is, the amputation is not congenital.
  • Refractory pain symptoms, following tissue healing(postoperatively, or post injury) are related to amputation as determined by referring physician and investigator, to include: stump pain, phantom pain, unpleasant phantom sensations, and/or undesirable and/or life-limiting kinesthetic sensations. The character, frequency, location, description, and exacerbation or relieving elements will be recorded.

Patients will be questioned as to the location of their sensation, be it pain, movement, burning, tingling, or other. The location of their pain will be correlated with the corresponding proximal nerve stump.

  • Positive anesthetic/steroid block, as performed under CT guidance in an analogous fashion to the cryoablation procedure.
  • Absence of infection
  • Absence of coagulopathy
  • Ability and willingness of patient to provide written informed consent

Exclusion Criteria:

  • Active infection
  • Underlying congenital segmentation or other spinal anomalies that result in differential nerve root pressures
  • Significant spinal stenosis interpreted as "severe" on any cross sectional imaging study
  • Pregnant or planning to become pregnant
  • Immunosuppression
  • History or laboratory results indicative of any significant cardiac, endocrine, hematologic, hepatic, immunologic, infectious, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, neoplastic, or other disorder that in the opinion of the Principal Investigator would preclude the safe performance of cryoablation.
  • Uncorrectable coagulopathies
  • Concurrent participation in another investigational trial involving systemic administration of agents or within the previous 30 days.
  • Have undergone a previous surgical intervention - post amputation - that may have altered the target nerve.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02366832

Layout table for location information
United States, Georgia
Emory University Hospital
Atlanta, Georgia, United States, 30322
Sponsors and Collaborators
Emory University
Boston Scientific Corporation
Layout table for investigator information
Principal Investigator: John D Prologo, MD Emory University
Additional Information:
Layout table for additonal information
Responsible Party: John Prologo, Assistant Professor, Emory University
ClinicalTrials.gov Identifier: NCT02366832    
Other Study ID Numbers: IRB00078008
First Posted: February 19, 2015    Key Record Dates
Last Update Posted: March 22, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Phantom Limb
Perceptual Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Pain, Postoperative
Postoperative Complications
Pathologic Processes